Antibiotic play Allecra raises EUR 22M
Allecra Therapeutics GmbH (Lorrach, Germany) raised EUR 22 million ($24.8 million) in an untranched series B round led by new investor Delos Capital. Existing investors Forbion Capital Partners, Edmond de Rothschild Investment Partners, EMBL Ventures and Allecra co-founder and CEO Nicholas Benedict also participated.
Allecra is developing antibiotics to treat multidrug-resistant Gram-negative bacterial infections in hospitals. In 1H17, the company plans to start Phase II testing of lead compound AAI202. Benedict said potential indications include those for which AAI202 has Qualified Infectious Disease Product (QIDP) designation from FDA: complicated intra-abdominal infections (cIAIs), complicated urinary tract infections (cUTIs), hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP). ...